Zobrazeno 1 - 10
of 141
pro vyhledávání: ''
Autor:
Sara Hultberg, Kurt Wahlstedt, Margareta Reis, Jörgen Rosén, Kristoffer N.T. Månsson, Olof R. Hjorth, Malin Gingnell, Vanda Faria, Andreas Frick, Johanna M. Hoppe, Mark Lubberink, Mats Fredrikson, Iman Alaie, Tomas Furmark, Gunnar Antoni, My Jonasson
Publikováno v:
Translational Psychiatry, Vol 11, Iss 1, Pp 1-8 (2021)
Translational Psychiatry
Translational Psychiatry
It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporte
Autor:
Patricia M. L. A. van den Bemt, Ingrid A. Boere, Roelof W F van Leeuwen, Esther Oomen-de Hoop, Juul M. Cox, Tessa M. Bosch, Ruben Malmberg, Leni van Doorn, Agnes Jager, Ron H.J. Mathijssen
Publikováno v:
British Journal of Cancer, 124(10), 1647-1652. Nature Publishing Group
Background: Ranitidine, a histamine 2 blocker, is the standard of care to prevent hypersensitivity reactions (HSRs) caused by paclitaxel infusion. However, the added value of ranitidine in this premedication regimen is controversial. Therefore, we co
Autor:
Pavel Jindra, Riita Niittyvuopio, Hervé Tilly, Jakob Passweg, Gesine Bug, Dietrich W. Beelen, Klaus Hirschbühl, Bruno Lioure, Mohamad Mohty, Arnon Nagler, Jan J. Cornelissen, Sebastian Giebel, Hélène Labussière-Wallet, Myriam Labopin, Mohamed Houhou, C. Schmid, Gerald Wulf, Ludovic Gabellier
Publikováno v:
Bone Marrow Transplantation, 56(5), 1190-1199. Nature Publishing Group
Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for pers
Autor:
Jacalyn Rosenblatt, Diane Warren, Kelly Masone, Dena Grayson, Sascha A. Tuchman, Kathleen Colson, Paul G. Richardson, Jacob P. Laubach, Robert A. Redd, Constantine S. Mitsiades
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a med
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Paraneoplastic pemphigus (PNP) is a severe autoimmune syndrome commonly triggered by neoplasms. The prognosis of CLL-associated PNP is dismal due to its refractory course and secondary infection and no standard treatment was recommended. We retrospec
Autor:
Cecilie L. Bager, M. H. Tang, Anne-Christine Bay-Jensen, Søren Brunak, P. Frederiksen, Morten A. Karsdal, Joseph P.M. Blair
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Blair, J P M, Bay-Jensen, A-C, Tang, M H, Frederiksen, P, Bager, C, Karsdal, M & Brunak, S 2020, ' Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis ', Scientific Reports, vol. 10, no. 1, 13975 . https://doi.org/10.1038/s41598-020-70942-x
Scientific Reports
Blair, J P M, Bay-Jensen, A-C, Tang, M H, Frederiksen, P, Bager, C, Karsdal, M & Brunak, S 2020, ' Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis ', Scientific Reports, vol. 10, no. 1, 13975 . https://doi.org/10.1038/s41598-020-70942-x
Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify varia
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
The treatment of testicular cancer includes unilateral orchiectomy and chemotherapy and is curative for most patients. However, observational studies revealed an association with depression, anxiety and cognitive impairment. It is unclear whether the
Autor:
Binghe Xu, Wei Li, Yeon Hee Park, W. Wu, Quchang Ouyang, Mark E. Robson, Seock-Ah Im, Ling Ming Tseng, Dah Cherng Yeh, C. Goessl, Joohyuk Sohn, Norikazu Masuda, Hiroji Iwata
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports
Scientific Reports
The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human
Autor:
Toshima Z. Parris, Peter Larsson, Elisabeth Werner Rönnerman, Per Karlsson, Eva Forssell-Aronsson, Jana Biermann, Hanna Engqvist, Khalil Helou, Anikó Kovács
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports
Scientific Reports
Cancer drug development has been riddled with high attrition rates, in part, due to poor reproducibility of preclinical models for drug discovery. Poor experimental design and lack of scientific transparency may cause experimental biases that in turn
Autor:
Hans Petter Brodal, Hanne E. Puntervoll, Leonardo A. Meza-Zepeda, Lars Birger Aasheim, Bjørn Tore Gjertsen, Rakel Brendsdal Forthun, Randi Hovland, Stian Knappskog, Oddbjørn Straume, Cornelia Schuster, Heidi M. Namløs
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Scientific Reports
Scientific Reports
Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastat